TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised $116.7 million in its initial public offering (IPO) in the United States, with the offering price at the lower end of its proposed price range

2026-10-09

TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised $116.7 million in its initial public offering (IPO) in the United States, with the offering price at the lower end of its proposed price range.